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ABSTRACT
The effect of self-monitoring of blood glucose (SMBG) on glycemic control with regard to non-insulin-
treated Type 2 diabetes mellitus (NIT-Type 2 DM) is still a controversial topic. Against this backdrop, 
we sought to compare the effect of a continuous short-term SMBG schema with as-usual treatment, 
based on changes in oral antidiabetic treatment in patients with poorly controlled Type 2 DM. We 
reviewed 492 NIT-Type 2 DM record charts, selecting 27 patients, with poor glycemic control, who were 
thought to self-monitor their blood glucose levels (SMBG group). We then compared them with 27 
patients treated with modifying drugs or diets to achieve and maintain the glycemic target (Control 
Group). Haemoglobin A1c (HbA1c) and fasting plasma glucose (FPG) were evaluated at baseline, after 
3 and 6 months. HbA1c values decreased after 3 and 6 months in the SMBG group (P < 0.001 on both 
SMBG and glycemic control in type 2 DM
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INTRODUCTION
Type 2 diabetes mellitus (Type 2 DM) is an 
extremely complex and chronic illness which usu-
ally requires continuous medical care.1 Its preva-
lence has been increasing steadily all over the 
world.1 The reduction in risk factors and the 
achievement of long-term good glycemic control 
are the two main goals of its management and in 
the prevention of short- and long-term 
complications.1
To the best of our knowledge, significant evi-
dence already exists and supports a range of 
interventions to improve diabetes outcomes.1 
Further, it has been widely demonstrated that the 
glycemic control in Type 2 DM depends on differ-
ent factors such as: (1) the disease’s natural evolu-
tion, (2) the progression of beta-cell failure, (3) 
the occurrence of concomitant diseases (cancers, 
infections, endocrine diseases, etc.), (4) the pro-
longed use of diabetogenic therapies (e.g., corti-
sone) and (5) poor patients’ compliance with 
treatment and inadequate lifestyle.1 In fact, good 
adherence to treatment remains a key strategy in 
avoiding or delaying the need for insulin 
replacement.2
The use of self-monitoring of blood glucose 
(SMBG) is recommended for Type 1 diabetes 
mellitus (Type 1 DM) and insulin-treated Type 2 
DM.1 However, the role of SMBG in patients 
with non-insulin-treated Type 2 DM (NIT-Type 2 
DM) remains controversial,1 due to conflicting 
results available in the literature, ranging from 
significant3–10 to absent11–14 improvements in hae-
moglobin A1c (HbA1c). That said, HbA1c reduc-
tion is generally minor,4 and SMBG alone does 
not seem to lower blood glucose levels; this 
knowledge must be factored into clinical and 
self-management plans.1,7
However, some of these studies involve meth-
odological limitations (i.e., HbA1c levels at base-
line are nearly within normal ranges; the absence 
of a standardized schema for SMBG, etc.). 
Moreover, they did not investigate the effective-
ness of SMBG, when used alone as a therapeutic 
strategy in improving glycemic control, and the 
usefulness of the optimal frequency and timing 
of SMBG. 
With this in view, the aim of  this study was 
to compare the effect of  the use of  a continu-
ous short-term SMBG schema for a limited 
period with the effect of  usual treatment 
changes in oral antidiabetic drug (OAD) treat-
ment and doses in patients with poorly con-
trolled Type 2 DM. Our hypothesis is that 
SMBG could increase patients’ awareness of 
the disease, in turn potentially ensuring the 
best adherence to treatment.
MATERIALS AND METHODS
Study Design
This is an observational retrospective study.
We reviewed 492 record charts of a group of 
patients with NIT-Type 2 DM who were under the 
same clinician and had been referred to the Diabetes 
Unit of the “Ospedale Civile Estense” Hospital in 
occasions) and in the control group (P < 0.05 and P < 0.01, respectively), but without a significant 
difference between the two groups when compared at the same time. The FPG progressively decreased 
in both groups, reaching a significant difference in the SMBG group after 3 months and in the control 
group after 6 months, and without a significant difference between the two groups. The SMBG schema 
used in our study could be adopted for target groups before proceeding to the next therapeutic 
enhancement drug step, representing a useful tool that can help diabetic patients in raising awareness 
of and treating their disease.
Keywords: glycated haemoglobin, non-insulin-treatmented type 2 diabetes, self-monitoring of blood 
glucose
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Modena, Italy. We eventually selected 27 patients, 
with poor glycemic control, who were thought to 
self-monitor their blood glucose levels (SMBG 
group), and then compared them with 27 patients 
treated by modifying their OAD  regimen (change 
in drug and/or dose) to achieve and maintain the 
glycemic target (control group) (Figure 1).
The patients in the SMBG group were selected 
from among those patients and handed a blood glu-
cometer and a diary to collect blood glucose levels to 
highlight any secondary failure or low compliance 
according to the usual clinical practice in our unit. 
In fact, these patients did not receive instruc-
tions either to interpret the SMBG data or to 
modify either their lifestyle habits (diet, physical 
activity) or the dose of the drug they were being 
treated with, that is, the dose was left unchanged. 
The patients in the SMBG group monitored their 
blood glucose according to the following 
regimen, which is arbitrarily used in the Diabetes 
Unit: three readings per day (one fasting control 
before breakfast and two postprandial controls 
after lunch and after dinner) over 2 days per week 
(one on working days and one at the weekend) 
(Figure 2), with the days when the readings are 
taken changed every week. The patients were also 
asked to perform an additional measurement 
whenever symptoms suggesting hypoglycemia or 
severe hyperglycemia occurred. 
Clinical and biochemical data were generally 
collected after 3 (Visit 2) and 6 months (Visit 3).
Subjects
We selected 54 record charts of subjects 
(25  males and 19 females) affected by Type 2 
DM  with poor glycemic control (HbA1c > 7%, 
53 mmol/mol) and assigned patients to one of the 
two groups in the study according to the clinical 
FIG 1. Flow-chart of the study design.
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approach used by the diabetologist (Figure 1): 
27 subjects in the SMBG group and 27 in the con-
trol group. The inclusion criteria were the follow-
ing: (1) diagnosis of Type 2 DM over a year ago, 
(2) being treated with OAD agents not reaching 
ceiling doses, (3) age > 45 years and (4) previous 
insulin administration for less than 1 week. The 
exclusion criteria were the following: (1) Type 1 
DM, (2) secondary DM, (3) serious diabetes com-
plications, (4) psychiatric illness, (5) history of 
alcohol or drugs abuse and (6) pregnancy. The 
adherence to glucose monitoring was evaluated by 
collecting data from the home diary and recorded 
by the blood glucometer, as reported on the record 
chart of selected patients. Compliance was defined 
as a monitoring frequency greater than 80% of 
the planned controls. Data from patients who did 
not comply with the suggested monitoring regi-
men were excluded from the study. 
On being diagnosed with DM, all the selected 
subjects underwent a nutritional assessment and 
received a home dietary schema. Physical activity 
was low to moderate for both groups of subjects. 
The data from 39 of  the 54 record charts were 
considered for final evaluation (Figure 1). 
Fifteen record charts (n = 8 in the SMBG group 
and n = 7 in the control group) were excluded 
because of  incomplete data, prolonged use of 
steroid therapy, major vascular events (cerebral 
stroke) and intercurrent disease (infection) 
(Figure 1).
Laboratory Assays
All blood samples were collected at 8.00 a.m. 
after an overnight fast.
HbA1c, blood glucose, microalbuminuria, total 
cholesterol, high density lipoproteins cholesterol 
(HDL cholesterol) and triglycerides were measured 
by using commercially available kits. 
STATISTICAL ANALYSIS
Statistical analysis was performed by using the 
“Statistical Package for the Social Sciences” 
FIG 2. Examples of focussed SMBG regimen: a comprehensive approach is to perform three tests per 
day (fasting, post-lunch and post-supper), two times per week (one variable from Monday to Friday 
representative of a weekday and one variable from Saturday to Sunday representative of a weekend 
day) and additional measurement in the event of suspected hypoglycemia or severe hyperglycemia.
software for Windows (Version 16.1; SPSS Inc., 
Chicago, IL).
Blood glucose, HbA1c, weight and body mass 
index (BMI) were the analysed parameters.
Statistical approach was performed by 
using per protocol analysis (19 subjects in the 
SMBG group and 20 in the control group).
Baseline parameters between the two 
groups (SMBG group vs. control group) were 
compared by two-side Analysis of Variance 
(ANOVA) uni-variate analysis. Similarly, 
the parameters obtained after 3 and 6 months 
in each of the two groups (SMBG group and 
control group) were compared with baseline 
values by using two-side ANOVA univariate 
analysis. Moreover, the change (increase or 
decrease) from baseline was calculated for each 
variable considered. The end-point change 
difference between two groups was evaluated by 
two-side ANOVA univariate.
Categorical data were compared between 
SMBG and control groups by using Fisher’s 
exact test.
For all comparisons, P values < 0.05 were con-
sidered statistically significant.
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ETHICAL COMMITTEE
Written informed consent for participation in 
the study was obtained from each subject. The 
local institutional review board (Comitato Etico 
di Modena) approved the study (N. 212/16).
RESULTS
The analysed data concern only the 39  subjects 
(19 in the SMBG group and 20 in the control 
group) with complete data (Figure 1). The two 
groups did not differ in terms of the baseline 
parameters (Table 1).
The data for the SMBG group are from 
19  patients: seven females (37%) and 12 males 
(63%), mean age 65 ± 7.7 years [mean ± 
standard deviation (SD)], mean duration of  
diabetes 10.6  ± 6.8 years (mean ± SD) (Table 1). 
The Control group data are from 20 patients: 
seven females (35%) and 13 males (65%), mean 
age 62.7 ± 9.6 years (mean ± SD), mean 
duration of diabetes 9.8 ± 9.1 years (mean ± 
SD) (Table 1).
All the patients were receiving OAD treat-
ment, that is, a combined oral therapy for the 
majority of  the subjects (63.2% of  the SMBG 
group and 60.0% of  the control group) 
(Table 1). The antidiabetic agents 
administrated as mono-therapy were: 
metformin for six subjects (31.6%) from the 
SMBG group and six subjects (30.0%) from 
the control group; sulphonylurea for 
one subject (5.3%) from the SMBG group and 
two subjects (10.0%) from the control 
group (Table 1).
Moreover, the control group comprised a 
lower number of patients with diabetic retinopa-
thy (one vs. three patients) (Table 1). Finally, 
subjects in the control group revealed a trend for 
higher triglycerides without a statistical differ-
ence, compared with the SMBG group. 
In both groups, no episodes of severe 
hypoglycemia were reported during the period 
examined on the record charts.
HbA1c
HbA1c values progressively and significantly
decreased after 3 and 6 months from baseline, 
both in the SMBG group [8.4 ± 0.6 vs. 7.7 ± 0.7% 
(68 ± 17 vs. 61 ± 16 mmol/mol), P < 0.001, and 
8.4 ± 0.6 vs. 7.5 ± 0.7% (68 ± 17 vs. 58 ± 
16 mmol/mol), P < 0.001, respectively] and in the 
control group [8.5 ± 1.0 vs. 8.0 ± 1.1% (69 ± 13 vs. 
64 ± 11 mmol/mol), P < 0.05 and 8.5 ± 1.0 vs. 
7.7  ± 1.0% (69 ± 13 vs. 61 ± 13 mmol/mol), 
P < 0.01, respectively] (Figure 3).
HbA1c value changes at the third and sixth 
months from baseline were not significantly dif-
ferent between the two groups (Table 2).
Glycemia
A progressive fasting plasma glucose (FPG)
decrease was observed in both groups during the 
study. However, this glycemic improvement was 
statistically significant in the SMBG group only at 
the third month versus baseline (175 ± 33.8 vs. 163 
± 25.8, P < 0.05), while it was only significant in 
the control group at the sixth month versus 
baseline (188.2 ± 46.1 vs. 159.1 ± 33.3, P < 0.05) 
with a trend for lower glycemia at the third month 
versus baseline (188.2 ± 46.1 vs. 165.4 ± 38.1, 
P = 0.06). Glycemia value changes at the third and 
sixth months from baseline were not significantly 
different between the two groups (Table 2).
 
Weight and BMI
    Significant changes in weight (data not shown)
and BMI (Table 2) were not observed in either of 
the two groups.
DISCUSSION AND CONCLUSIONS
In this observational retrospective study, we 
observed that the standard schema used for 
SMBG improved the glycemic profile in patients 
with poorly controlled NIT-Type 2 DM during
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Age (years) 65 ± 7.7 62.7 ± 9.6 0.33
Men 12 (63%) 13 (65%)
Duration of diabetes (years) 10.6 ± 6.8 9.8 ± 9.1 0.74
Diabetes treatment
 Mono-therapy 7 (36.8%) 8 (40%) 0.90
 Metformin 6 (31.6%) 6 (30%) 0.81
 Sulphonylurea 1 (5.3%) 2 (10%) 0.96
 Combined oral therapy 12 (63.2%) 12 (60%) 0.89
Diabetes related complications 
 Cardiovascular complications * 3 (15.7%) 2 (10%) 0.95
 Diabetic retinopathy 3 (15.7%) 1 (5%) 0.56
 Microalbuminuria 6 (31.5%) 6 (30%) 0.81
 Neuropathy 0 (0%) 1 (5%) 0.96
Cigarette consumption
 Never smoked 3 (15.7%) 3 (15%) 0.71
 Former smoker 7 (36.8%) 8 (40%) 0.90
 Current smoker 4 (21.0%) 5 (25%) 0.93
 Not specified 5 (26.3%) 4 (20%) 0.93
BMI (kg/m2) 28.1 ± 4.3 28.9 ± 4.6 0.58
HbA1c (%) 8.4 ± 0.6 8.5 ± 1.0 0.79
 HbA1c (mmol/mol) 68 ± 17 69 ± 13 0.79
FPG (mg/dl) 175 ± 33.7 188.2 ± 46.1 0.58
Total cholesterol levels (mg/dl) 199.0 ± 43.0 195.4 ± 55.6 0.84
HDL cholesterol levels (mg/dl) 49.7 ± 18.4 39.2 ± 13.0 0.07
Triglyceride levels (mg/dl) 132 ± 87.9 211 ± 151.8 0.09
BMI, body mass index; FPG, fasting plasma glucose; SMBG, self-monitoring of blood glucose; HbA1c, hba1c glycosylated hemoglobin 
A1c; HDL cholesterol, high density lipoproteins cholesterol.
Values are represented as mean ± standard deviation (SD) or percentages in parenthesis unless stated otherwise. *Altered ECG, 
previous acute myocardial infarction.
oral hypoglycemic treatment with no ceiling 
dos-age and without training on how to 
interpret their blood glucose readings.
Controversial data are available from 
the literature on the role of  SMBG in 
evaluating the effect on HbA1c,5,6,9–13 while 
only a few studies have investigated the 
effect on import-ant clinical end points 
instead of  HbA1c, such  as 
improvements in diabetes-related 
morbidity and mortality in patients with 
NIT-Type 2 DM.8
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TABLE 2. Changes in HbA1c Levels, Glycemia and BMI between Baseline and 3 and 6 Months 
Respectively, in SMBG Group and Control Group
Variable SMBG group Control group P value for difference between groups
HbA1c 
 Baseline
 % 8.4 ± 0.6 8.5 ± 1.0
 mmol/mol 68 ± 17 69 ± 13
 3 months
 % 7.7 ± 0.7 8.0 ± 1.1
 mmol/mol 61 ± 16 64 ± 11
 Change −0.7 ± 0.5 −0.5 ± 1.1 0.345
 6 months
 % 7.5 ± 0.7 7.7 ± 1.0
 mmol/mol 58 ± 16 61 ± 13
 Change −0.9 ± 0.7) −0.8 ± 1.1 0.620
Glycemia (mg/dL)
 Baseline 175.0 ± 33.8 188.2 ± 46.1
 3 months 163.0 ± 25.8 165.4 ± 38.1
 Change −12.1 ± 18.7 −22.9 ± 54.0 0.865
 6 months 160.3 ± 31.4 159.1 ± 33.3
 Change −14.7 ± 42.6 −29.2 ± 55.4 0.833
BMI (kg/m2)
 Baseline 28.1 ± 4.3 28.9 ± 4.6
 3 months 28.0 ± 4.4 29.0 ± 4.6 
 Change −0.1 ± 0.3 0.1 ± 0.4 0.458
 6 months 27.9 ± 4.4 29.1 ± 4.6
 Change −0.2 ± 0.5 0.1 ± 0.5 0.496
P-value, for difference between the two groups; BMI, body mass index; SMBG, self-monitoring of blood glucose.
Values are means (standard deviations).
The reason behind these discrepancies may be 
due to methodological differences such as 
inclusion criteria and the protocol of the 
intervention adopted: in particular, (1) the 
glycemic control at baseline, (2) the duration of 
the disease and (3)  training and support 
concerning the timing, interpretation and use 
of results to change drug prescriptions or
potential corrections of patients. For instance, in
the diabetes glycaemic education and monitoring 
study trial, poor SMBG efficacy in glycemic 
control could be related to an almost well-
controlled glycemic profile [mean HbA1c 7.5% 
(58 mmol/mol)] for patients with NIT-Type 2
SMBG and glycemic control in type 2 DM
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 DM12,15 at the time of enrolment. However, to 
achieve significant results, a larger sample of 
patients is needed.10 In contrast with the present 
study, patients with poorer glycemic control 
were selected. In fact, according to previous 
studies, a higher level of HbA1c at baseline 
represents a predictive factor concerning an 
improvement in glycemic control by SMBG,6 as 
confirmed by Young et al.,14 even if this effect 
on HbA1c is lost in long-term follow-up.14
The ESMON 1-year trial13 showed that SMBG 
did not improve glycemic control in NIT-Type 2 
DM, but the subjects in this trial had had a recent 
diagnosis of diabetes, while, in this study, patients 
had a longer duration of illness. These results 
only support the conclusion that a rapid and 
major improvement in glycemic control, due to 
the initiation or aggressive use of 
antidiabeticagents, could limit the contribution 
of SMBG to disease management.
Unlike other several studies suggesting the 
effectiveness of SMBG in improving glycemic 
control in patients with NIT-Type 2 
DM,3–7,9,16 in our case, patients were not 
given any information about the blood glucose 
target to be achieved or changes in lifestyle (diet, 
physical activity) to be implemented. Because we 
did not monitor adherence to therapy, physical 
activity and changes to diet of patients with 
validated tools, we can only speculate that the 
improvement obtained by SMBG in our study 
could be the result of enhancing motivation and 
maintaining adherence to diet, physical activity 
and drug regimens, informed by an awareness of 
abnormal glucose values. Taking into account 
that many patients are unaware of the disease, 
because Type 2 DM is not generally 
accompanied by significant symptoms, as is the 
case with other chronic diseases. This lack of      
 significant symptoms and the consequential lack
of awareness of  the disease could explain the
poor adherence to therapy in most patients.2
However, it is noteworthy that all our patients
were not administrated a ceiling dosage; thus,
they were not involved in a secondary failure to
oral hypoglycemic agents, and it could be
assumed that such results would have been out
of  reach if  our patients had been at the ceiling
dosage. Moreover, another possible explanation
of SMBG efficacy in relation to glycemic control
in our study could be the “novelty procedure
effect.” Accordingly, our patients were new users
of the SMBG procedure, and this could be a
short-term effect.17
A further important aspect was the SMBG 
schema used among our patients. Most previous 
studies provide information on the protocol 
(intensity and frequency) used5,12 or use a 
standard protocol, merely to indicate the total 
number of daily or weekly blood glucose 
checks.6,13 However, the usefulness, optimal 
frequency and timing of SMBG in patients with 
NIT-Type 2 DM remain unclear. In our study, 
we used a standard self-control regimen as 
previously described (Figure 2), which, although 
arbitrary, was based on a criterion of maximum 
reading representation, with minimal discomfort 
for the patient. Considering that SMBG can 
raise the level of stress,18 we have reduced the 
frequency of measurements to maintain the 
highest representation of glycemic variability 
linked to different daily activities and provide a 
good representation of the blood glucose 
variability during the week under ordinary 
conditions, with the least possible number of 
measurements. Hence, due to the improvement 
in glycemic control achieved with    
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the proposed SMBG schema, we suggest its 
adoption as a strategy in patients with poorly 
controlled NIT-Type 2 DM, before implementing 
the drug therapy.
Furthermore, as reported by other studies,5 
in our case, body weight was not reduced 
during the follow-up. This could indirectly 
indicate that improvements in blood glucose 
pro-files seen in our study were not because of 
weight loss, as the latter is considered to be an 
effective therapeutic strategy in the treatment 
of Type 2 DM.1
Our study involves some limitations, the fore-
most of which are the retrospective design, the 
short-term duration of follow-up and the small 
sample size. Accordingly, even though the patients 
included in the study were to minimize selection 
bias, the latter may be not completely avoided due 
to the retrospective nature of the study. Moreover, 
data were obtained from a single unit by applying 
one treatment protocol, which meant that 
external validation was required. Hence, future 
research should be designed by taking these   
 
 limitations into account. Nevertheless, 
important clinical implications can be evinced 
from the study. First, taking into account the 
most recent literature suggesting that self-
monitoring may be useful when coupled with a 
treatment adjustment programme,1 clinicians 
should be aware of the effectiveness of SMBG 
as a strategy that can improve glycemic control 
in patients with poorly controlled Type 2 DM 
receiving OAD agents with no ceiling dosage. In 
addition, this finding should be emphasized and 
discussed with patients as a possible 
motivational aid.
In conclusion, the standard SMBG regimen 
used in our study could be an option to treat target 
groups, in particular, patients with poorly con-
trolled NIT-Type 2 DM (HbA1c > 8%) and not 
with a recent diagnosis, before proceeding to the 
next therapeutic enhancement drug step. This is 
because SMBG could be a useful tool, which can 
help diabetic patients in raising awareness of and 
treating their disease.
FIG 3. Change in HbA1c levels after 3 and 6 months in self-monitoring of blood glucose (SMBG) 
group and control group. The dark grey column represents HbA1c value at baseline; grey column 
represents HbA1c value at 3 months; and white represents HbA1c value at 6 months. Values are 
represented as mean ± standard deviation (SD). *ANOVA was used.
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